SYK
Stryker Corporation
NYSE · Healthcare · Medical - Devices · US
$304.21
−1.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.8B | 25.1B | 22.6B | 20.5B | 18.4B |
| Cost of Revenue | 9.0B | 9.1B | 8.6B | 8.0B | 7.4B |
| Gross Profit | 16.8B | 16.1B | 14.0B | 12.5B | 11.0B |
| Operating Expenses | |||||
| R&D Expense | 1.7B | 1.6B | 1.4B | 1.3B | 1.2B |
| SG&A Expense | 8.8B | 8.7B | 7.5B | 6.9B | 6.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 706.0M | 902.0M | — | — | — |
| Total Operating Expenses | 11.1B | 11.2B | 8.9B | 8.2B | 7.3B |
| Cost and Expenses | 20.1B | 20.2B | 17.5B | 16.2B | 14.7B |
| Operating Income (EBIT) | 5.7B | 4.9B | 5.1B | 4.3B | 3.7B |
| Non-Operating | |||||
| Interest Income | 28.0M | 121.0M | 139.0M | 75.0M | 94.0M |
| Interest Expense | 686.0M | 607.0M | 396.0M | 356.0M | 337.0M |
| Net Interest Income | (658.0M) | (486.0M) | (257.0M) | (281.0M) | (243.0M) |
| Other Non-Op Income/Expense | (543.0M) | (375.0M) | (1.6B) | (608.0M) | (1.1B) |
| Non-Operating Income (excl Interest) | 386.0M | (232.0M) | 1.2B | 252.0M | 714.0M |
| EBT (Pre-Tax Income) | 5.1B | 4.5B | 3.5B | 3.7B | 2.7B |
| Income Tax Expense | 1.4B | 1.3B | 499.0M | 508.0M | 325.0M |
| Bottom Line | |||||
| Net Income | 3.7B | 3.2B | 3.0B | 3.2B | 2.4B |
| Earnings from Cont. Ops | 3.7B | 3.2B | 3.0B | 3.2B | 2.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.7B | 3.2B | 3.0B | 3.2B | 2.4B |
| Per Share | |||||
| Basic EPS | $9.73 | $8.49 | $7.86 | $8.34 | $6.23 |
| Diluted EPS | $9.65 | $8.40 | $7.76 | $8.25 | $6.17 |
| Revenue Per Share | $67.37 | $65.71 | $59.30 | $54.00 | $48.78 |
| Shares | |||||
| Basic Shares Outstanding | 383.5M | 382.2M | 381.0M | 379.6M | 378.2M |
| Diluted Shares Outstanding | 386.0M | 382.2M | 385.6M | 383.7M | 382.2M |
| Profitability Metrics | |||||
| EBITDA | 6.3B | 6.3B | 4.9B | 5.1B | 4.0B |
| D&A | 950.0M | 1.2B | 1.1B | 1.0B | 998.0M |
| EBIT | 5.3B | 5.1B | 3.9B | 4.0B | 3.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026